Trial Profile
A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Jun 2022 Results (n=13) assessing the changes in the tumor immune microenvironment (TiME) induced by talazoparib, published in the Clinical Cancer Research.
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.
- 09 Feb 2022 Planned End Date changed from 30 Apr 2021 to 30 Apr 2022.